Cardiometabolic Disorders News

Adults who eat more foods associated with a Mediterranean diet have lower blood pressure, BMI and reduced cardiovascular risk, according to study findings published in Nutrition, Metabolism & Cardiovascular Diseases.

PHILADELPHIA — Recaticimab, a novel anti-PCSK9 drug, conferred significant LDL reductions at 48 weeks in a cohort of patients with mixed hyperlipidemias already on statin therapy, a speaker reported.

Adults who exercise in the morning have a lower BMI and waist circumference than those who exercise in the afternoon or evening, according to study findings published in Obesity.

PHILADELPHIA — In this Healio exclusive, Deepak L. Bhatt, MD, MPH, provides his perspective on research presented at the American Heart Association Scientific Sessions.

PHILADELPHIA — In a phase 1 study, lepodisiran was well-tolerated and produced dose-dependent reductions in lipoprotein(a) concentrations in adults without CVD who had elevated lipoprotein(a) levels.

PHILADELPHIA — A novel single-dose CRISPR base-editing infusion for patients with heterozygous familial hypercholesterolemia and advanced CAD reduced serum PCSK9 and lowered LDL by up to 55% in one patient, a speaker reported.

PHILADELPHIA — In patients without diabetes or heart failure presenting with acute MI and impaired left ventricular function, dapagliflozin improved cardiometabolic outcomes compared with placebo, according to the DAPA-MI trial.

PHILADELPHIA — In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg was superior to placebo for reducing cardiovascular risk in adults with preexisting heart disease and overweight or obesity but without diabetes.

Adults with type 2 diabetes and obesity achieved greater weight loss with time-restricted eating at 6 months than with calorie restriction or continuing usual eating habits, according to study data.

Healio and Cardiology Today have aggregated news you may have missed from the 2023 Cardiometabolic Health Congress in Boston.